SECOND AMENDMENT TO ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENT
Exhibit 10.2
SECOND AMENDMENT TO ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENT
This Second Amendment to Oncosignature Companion Diagnostic Agreement (the “Second Amendment”) is made and entered into as of June 19, 2023 (the “Second Amendment Effective Date”) by and between:
Acrivon Therapeutics, Inc., a Delaware corporation with its principal place of business at 000 Xxxxxxx Xxx, Xxxxx 000, Xxxxxxxxx, XX 00000 (“Acrivon”), and
Akoya Biosciences, Inc., a Delaware corporation with its principal place of business at 000 Xxxxxx Xxxxx, 0xx xxxxx, Xxxxxxxxxxx, XX 00000 (“Akoya”).
Acrivon and Xxxxx are each referred to individually as a “Party” and together as the “Parties.”
WHEREAS, Acrivon and Xxxxx are parties to that certain Oncosignature Companion Diagnostic Agreement, dated June 17, 2022, as amended on December 21, 2022 (the “Agreement”), under which the Parties are collaborating to develop, validate, obtain regulatory approval for, and commercialize a companion diagnostic test for use with Prexasertib; and
Whereas, the Parties now wish to amend certain terms of the Agreement, as set forth in more detail below.
Now therefore, in consideration of the mutual promises and agreement set forth herein, and for other good and valuable considerations, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
[Signature Page Follows]
In Witness Whereof, the Parties have executed this Second Amendment in duplicate originals by their proper officers as of the Second Amendment Effective Date.
Xxxx: Xxxx Xxxxxx Xxxx: June 19, 2023 |
Akoya Biosciences, Inc.
Xxxx: Xxxxxx Xx Xxxx: June 20, 2023 |
Exhibit A
Schedule 3.5
Development Milestones; Development Milestone Payments
[***]